Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

Among the pharmaceutical options available for treatment of ovarian cancer, attention has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies. Currently, single agent trabectedin is approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascilini, Floriana, Amadio, Giulia, Di Stefano, Maria Grazia, Ludovisi, Manuela, Di Legge, Alessia, Conte, Carmine, De Vincenzo, Rosa, Ricci, Caterina, Masciullo, Valeria, Salutari, Vanda, Scambia, Giovanni, Ferrandina, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103925/
https://www.ncbi.nlm.nih.gov/pubmed/25050069
http://dx.doi.org/10.2147/OTT.S51550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103925/
https://www.ncbi.nlm.nih.gov/pubmed/25050069
http://dx.doi.org/10.2147/OTT.S51550

Ejemplares similares